On April 27, 2026 Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, reported that an abstract highlighting preclinical data from SG293, its CD19-directed in vivo CAR T product candidate, has been accepted for oral presentation at the American Society of Gene & Cell Therapy (ASGCT) (Free ASGCT Whitepaper) 2026 Annual Meeting taking place May 11-15, 2026 in Boston, MA.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Oral Presentation:

Title: Potent, safe, and cell-specific in vivo generation of CAR-T cells in NHPs with SG293
Summary: SG293 represents a differentiated approach for enabling potent and precise in vivo CAR T therapy for both oncology and autoimmune indications, potentially avoiding key off-target concerns.
Session: Advancing in vivo gene delivery with non-AAV viral vector systems
Session Location: MCEC Room 257AB (Level 2)
Session Date/Time: Tuesday, May 12, 2026; 8:00 – 9:45 a.m. ET
Presentation Time: 8:15 – 8:30 a.m. ET
Abstract Number: 20

The ASGCT (Free ASGCT Whitepaper) abstract is available to the public at: View Source

About SG293
SG293, which uses Sana’s proprietary fusogen-based delivery technology, is a CD8-targeted fusosome that delivers to CD8+ T cells the genetic material to make CD19-directed CAR T cells while avoiding potentially troublesome delivery to tissues such as the liver. The fusogen technology is designed to enable cell-specific delivery of material that integrates into the DNA of the target cell. Sana intends to explore SG293 in both B-cell cancers and B-cell mediated autoimmune diseases.

(Press release, Sana Biotechnology, APR 27, 2026, View Source [SID1234664804])

On April 27, 2026 Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, reported the pricing of an underwritten offering of 29,166,700 shares of its Series A common stock at a price of $6.00 per share. The gross proceeds from the offering are expected to be approximately $175.0 million, before deducting underwriting discounts and commissions and other offering expenses. All of the shares in the offering are to be sold by Sagimet. The offering is expected to close on or about April 28, 2026, subject to the satisfaction of customary closing conditions.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The financing included participation from new and existing investors, including Balyasny Asset Management, Blue Owl Healthcare Opportunities, BVF Partners L.P., Caligan Partners, Coastlands Capital, Farallon Capital Management, Great Point Partners, LLC, Woodline Partners LP and a Large Mutual Fund.

Leerink Partners, TD Cowen, Guggenheim Securities and Oppenheimer & Co. are acting as joint bookrunning managers for the offering. Canaccord Genuity, H.C. Wainwright & Co. and Jones are acting as co-lead managers for the offering.

Sagimet intends to use the net proceeds from the offering, together with its existing cash, cash equivalents and marketable securities, to fund a Phase 3 clinical trial for denifanstat in acne, fund TVB-3567 through Phase 2 topline results, advance a topical formulation FASN inhibitor to IND submission and for general corporate purposes, including additional clinical development, working capital and operating expenses. The Company currently expects that its existing cash and cash equivalents, together with the proceeds from the offering, will fund its acne programs through 2028 and the readout of the Company’s planned denifanstat Phase 3 clinical trial in moderate to severe acne.

A shelf registration statement on Form S-3 (File No. 333-281582) relating to these shares was filed with the Securities and Exchange Commission (the "SEC") and declared effective on August 26, 2024. A prospectus supplement relating to the offering, and the accompanying prospectus, will be filed with the SEC. When available, copies of the prospectus supplement and accompanying prospectus may also be obtained from the offices of Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at (800) 808-7525, ext. 6105, or by email at [email protected]; TD Securities (USA) LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at [email protected]; or Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, by telephone at (212) 518-9544, or by email at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these shares, nor will there be any sale of these shares in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state, province, territory or other jurisdiction.

(Press release, Sagimet Biosciences, APR 27, 2026, View Source [SID1234664836])

On April 27, 2026 Jecho Laboratories, Inc. ("Jecho"), a clinical-stage biotechnology company focused on developing innovative therapeutics, reported that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for JLM019.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

JLM019 is a CD80/PD-1 dual-target Fc fusion protein with a unique bidirectional synergistic mechanism. With its precise targeting design, the drug is expected to overcome the limitations of existing immunotherapies, improve immunotherapy response rates, and delay the development of tumor cell resistance. As a result, it has the potential to significantly enhance immunotherapy and provide new treatment options and hope for survival for patients with advanced solid tumors and lymphomas.

JLM019 is currently in a Phase 1 study for advanced malignant tumors in Peking Union Medical College Hospital, as it was approved to commence clinical trials by China’s National Medical Products Administration (NMPA) in September 2025. The Phase 1 study is designed to evaluate the safety, tolerability, and preliminary efficacy of JLM019 injection in patients with advanced malignancies.

This achievement marks the third U.S. FDA IND clearance Jecho has obtained and the 11th overall IND clearance.

(Press release, Jecho Laboratories, APR 27, 2026, View Source [SID1234664969])

On April 27, 2026 Eli Lilly and Company (NYSE: LLY) and Ajax Therapeutics, Inc. ("Ajax"), a biopharmaceutical company developing next generation JAK inhibitors for patients with myeloproliferative neoplasms (MPNs), reported a definitive agreement for Lilly to acquire Ajax. Ajax’s lead asset, AJ1-11095, is an investigational, once-daily oral, first-in-class Type II JAK2 inhibitor currently being evaluated in a Phase 1 clinical trial, AJX-101, in patients with myelofibrosis who have previously been treated with a Type I JAK2 inhibitor.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

All approved JAK2 inhibitors for patients with MPNs, including myelofibrosis and polycythemia vera, bind the Type I confirmation of JAK2. While these JAK2 inhibitors provide clinical and symptomatic relief, many patients often discontinue Type I JAK2 treatment due to a lack of durable benefit or loss of response. AJ1-11095 was designed as a selective Type II JAK2 inhibitor to not only deliver deeper and more durable efficacy than existing JAK2 inhibitors but also to provide a novel treatment option for those patients who become resistant to Type I JAK2 inhibitors. The Phase 1 clinical trial of AJ1-11095 began in late 2024 and dose selection for future clinical development is expected in 2026.

"As a founding strategic investor in Ajax, Lilly has long believed in the approach and is excited about the potential for AJ1-11095 to deliver deeper and more durable efficacy than available treatments with a tolerability profile that would allow for patients to remain on therapy longer and be used across both the first- and second-line settings," said Jacob Van Naarden, executive vice president and president of Lilly Oncology and head of corporate business development. "We look forward to the presentation of clinical proof-of-concept data later in 2026, rapidly advancing AJ1-11095 into registrational clinical trials, and using our expertise in blood cancer to hopefully deliver another important new medicine to patients and hematologists."

"We started Ajax to build on the work of its five scientific founders, including Ross Levine, MD, chief scientific officer at Memorial Sloan Kettering Cancer Center and chair of Ajax’s scientific advisory board, who sought to develop a novel class of selective and more potent JAK2 inhibitors to address the significant unmet need of patients with MPNs," said Martin Vogelbaum, co-founder and chief executive officer of Ajax Therapeutics. "With a small but highly motivated team, we have successfully applied this work to the design and development of our highly selective, first-in-class Type II JAK2 inhibitor, AJ1-11095. We now look forward to Lilly advancing AJ1-11095 through the clinic and providing a much-needed new therapy for patients with MPNs. It has been an honor working with our employees and scientific advisors and we’re grateful to our clinical investigators, and most importantly, the patients who have participated in our ongoing Phase 1 study, AJX-101."

Under the terms of the agreement, Lilly will acquire Ajax and Ajax shareholders could receive up to $2.3 billion in cash, inclusive of an upfront payment and subsequent payments upon the achievement of certain clinical and regulatory milestones.

The transaction is subject to customary closing conditions, including approval under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. Lilly will determine the accounting treatment of this transaction following closing in accordance with Generally Accepted Accounting Principles (GAAP). This transaction will thereafter be reflected in Lilly’s financial results and financial guidance.

For Lilly Ropes Gray LLP is acting as legal counsel. For Ajax, Cooley LLP is acting as legal counsel. Kirkland & Ellis LLP also provided legal advice to Ajax.

(Press release, Eli Lilly, APR 27, 2026, View Source [SID1234664789])

On April 27, 2026 Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona"), reported that its Chief Medical Officer, Dr. Carman Giacomantonio presented data from its first-in-human early feasibility study for its Targeted Hyperthermia Therapy cancer treatment at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) ("AACR") last week in San Diego. Dr. Giacomantonio has also been accepted to present Sona’s data at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) ("ASCO") annual meeting May 29 – June 2, 2026, a conference centered on scientific innovation and its translation into practical patient-centered clinical application.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Giacomantonio commented, "AACR is the premier stage for sharing breakthrough science, and it was exciting to see our Targeted Hyperthermia Therapy align so well with the conference’s focus on overcoming immunotherapy resistance. The feedback we received on our clinical study was incredibly encouraging and confirms for us that we’re on the right path toward offering new hope to patients who have run out of options. Next, we are delighted to have been invited to share our compelling data to the more industry-focused ASCO (Free ASCO Whitepaper) conference."

The presentation highlights the initial safety, tolerability and anti-tumor activity from this study which demonstrated a complete response in treated indicative tumors in six out of ten late-stage melanoma patients who had previously failed on standard of care immunotherapy. This study is a critical milestone in the Company’s mission to treat immunotherapy-resistant solid tumors in humans. A manuscript detailing these results is currently being prepared for submission to a leading peer-reviewed scientific journal.

Sona’s first-in-human study results speak to a persistent unmet need that remains the dominant conversation in the melanoma community. The Melanoma Research Alliance noted in October 2025 that roughly half of advanced melanoma patients still do not respond to — or develop resistance to — currently approved immunotherapies. Sona’s study was conducted in patients from precisely this refractory group.

Next month’s ASCO (Free ASCO Whitepaper) annual meeting is the world’s most significant gathering of oncology professionals, serving as the premier global stage for the unveiling of practice-changing clinical research. Each year, more than 40,000 oncology experts, patient advocates, and industry leaders from over 150 countries convene to present and discuss the latest advances in clinical cancer care. Known for its focus on the "bench-to-bedside" transition, the meeting features groundbreaking abstracts and clinical trial results that directly influence the standard of care for patients worldwide.

(Press release, Sona Nanotech, APR 27, 2026, View Source [SID1234664805])